Q-omics provides the consensus-scored RPL21P129 profile across patient tissues and cancer cell-line models. RPL21P129 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RPL21P129 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, RPL21P129 RNA expression shows 6,034 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, THCA, and STAD as cancer lineages where RPL21P129 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P129 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P129 survival associations across molecular data types. RPL21P129 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P129 RNA expression–survival associations across cancer types. High RPL21P129 expression shows unfavorable associations in ACC, OV, UVM and KICH, but favorable associations in UCS and CESC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for RPL21P129 RNA expression.
This table summarizes RPL21P129 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P129. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P129 shows higher tumor expression in THCA, COAD and LIHC. The THCA box plot shows higher RPL21P129 RNA expression in tumor versus normal tissue (log2 FC = +0.156, t-test p = .010).
This table shows molecular features associated with RPL21P129 in patient tissues and cancer cell lines. In patient samples, RPL21P129 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
